

COMPLIANCE CERTIFICATE

(Pursuant to Regulation 163(2), Part III of Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations 2018 including any amendment/modification thereof)

**To The Board of Directors,
Balaxi Pharmaceuticals Limited**

Plot No.409, H.No. 8-2-293,
Maps Towers ,3rd Floor, Phase III,
Road No.81, Jubilee Hills, Hyderabad
Telangana- 500096

I , Yogindunath S, Designated Partner, BVR and Associates Company Secretaries LLP, Swastika, Chitteth Building, PC Road, Ponnuruni East, Vytila PO, Cochin- 682019 Company Secretaries have been appointed on 01st September 2022 by Balaxi Pharmaceuticals Limited (hereinafter referred to as 'Company'), having CIN: L25191TG1942PLC121598 and having its Registered Office at Plot No.409,H.No. 8-2-293, Maps Towers 3rd Floor, Phase-III, Road No.81,Jubilee Hills Hyderabad-500096, to issue this Compliance Certificate in accordance with Regulation 163(2) of Chapter V of SEBI (Issue of Capital and Disclosure Requirements), Regulations, 2018 as amended from time to time, (hereinafter referred to as "Regulations").

In accordance with the Regulations, the Company has proposed to issue shares on a preferential basis ('Proposed Preferential issue'). The proposed preferential issue was approved at the Meeting of Board of Directors of the Company held on 05/09/2022.

Based on my examination of such information, documents and explanation provided to me by the management and employees of the Company, I hereby certify that proposed preferential issue is being made in accordance with the requirements of the Regulations.

For BVR & ASSOCIATES COMPANY SECRETARIES LLP

**Date: 05/09/2022
Place: Cochin**




**CS YOGINDUNATH S
DESIGNATED PARTNER
MEMBERSHIP No.7865
CP No.9137
UDIN: F007865D000915123**